Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA

Gaffney, Karl ORCID:, Gullick, Nicola, Mackay, Kirsten, Patel, Yusuf, Sengupta, Raj, Sheeran, Tom, Hemmings, Louise and Pamies, Paula (2023) Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA. Rheumatology Advances in Practice, 7 (3). ISSN 2514-1775

[thumbnail of Gaffney_etal_2023_RAP_rkad055]
PDF (Gaffney_etal_2023_RAP_rkad055) - Published Version
Available under License Creative Commons Attribution.

Download (480kB) | Preview


Objectives: The aim was to evaluate retention rates for secukinumab in patients with active PsA or radiographic axial spondyloarthritis (r-axSpA) treated in routine UK clinical practice. Methods: SERENA (CAIN457A3403) is an ongoing, non-interventional, international study of patients with moderate-to-severe chronic plaque psoriasis, active PsA or active r-axSpA, who had received secukinumab for ≥16 weeks before enrolment. The primary objective of this interim analysis was to assess treatment retention rates in patients with PsA or r-axSpA who were enrolled and followed for ≥2 years at centres in the UK. The safety analysis set includes all patients who received at least one dose of secukinumab. The target population set includes all patients who fulfilled the patient selection criteria. Results: The safety set comprised 189 patients (PsA, n = 81; r-axSpA, n = 108), and the target population set comprised 183 patients (PsA, n = 78; r-axSpA, n = 105). In the safety set, 107 patients (45 of 81 with PsA and 62 of 108 with r-axSpA) had previously received a biologic agent. Retention rates were similar between patients with PsA and r-axSpA after 1 year (PsA 91.0%, 95% CI: 84.0, 98.0; r-axSpA 89.2%, 95% CI: 82.7, 95.7) and 2 years (PsA 77.6%, 95% CI: 67.6, 87.7; r-axSpA 76.2%, 95% CI: 67.4, 85.0) of observation. Overall, 17.5% of patients (33 of 189) experienced at least one treatment-related adverse event, and 12.7% of patients (24 of 189) discontinued secukinumab because of adverse events. Conclusion: This analysis of real-world data from the UK demonstrates high retention rates for secukinumab over 2 years in patients with PsA or r-axSpA, with a favourable safety profile.

Item Type: Article
Additional Information: Funding Information: This work was supported by Novartis Pharma AG. Further Information: Medical writing support was provided by Blair Jarvis, MSc and Imogen Allred, DPhil, of OPEN Health Communications (London, UK) and funded by Novartis Pharmaceuticals UK Ltd. Some of these data were presented at a Novartis Promotional Dinner as a presentation entitled ‘Updates in Rheumatology at Novartis’. Note on citation information: the journal website gives the issue number as 3 but the PDF version of the article gives the issue number as 2.
Uncontrolled Keywords: drug survival,psa,radiographic axial spondyloarthritis,real-world evidence,secukinumab,rheumatology ,/dk/atira/pure/subjectarea/asjc/2700/2745
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 02 Dec 2023 03:34
Last Modified: 02 Dec 2023 03:34
DOI: 10.1093/rap/rkad055


Downloads per month over past year

Actions (login required)

View Item View Item